D-serine mitigates cell loss associated with temporal lobe epilepsy

Area of Science:

• Neuroscience
• Epileptology
• Pharmacology

Background:

• Temporal lobe epilepsy (TLE) is the most common adult epilepsy, often resistant to drugs.
• A key feature of TLE is the loss of layer 3 neurons in the medial entorhinal area (MEA), contributing to seizures.
• Understanding TLE's pathophysiology is crucial for developing effective interventions.

Purpose of the Study:

• To investigate the role of neurons and glia in TLE pathology.
• To evaluate D-serine as a potential therapeutic agent for TLE.
• To determine D-serine's effects on neuronal loss and neuroinflammation in TLE.

Main Methods:

• Focal administration of D-serine to the MEA in an animal model of TLE.
• Assessment of neuronal loss, astrocyte counts, and microglial activity.
• Evaluation of D-serine's impact on epileptogenesis and neuroinflammation.

Main Results:

• D-serine administration attenuated neuronal loss in the MEA, preventing epileptogenesis.
• Treatment with D-serine reduced astrocyte numbers and altered their reactive state.
• D-serine mitigated microglial proliferation and/or infiltration, reducing neuroinflammation.

Conclusions:

• D-serine, an endogenous amino acid, effectively mitigates TLE pathology in an animal model.
• D-serine demonstrates neuroprotective and anti-inflammatory properties relevant to TLE.
• D-serine represents a promising therapeutic candidate for refractory TLE due to its multifaceted benefits.